Vir Biotechnology Announces Board and Executive Changes
Ticker: VIR · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1706431
| Field | Detail |
|---|---|
| Company | Vir Biotechnology, Inc. (VIR) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Vir Bio shakes up board & exec pay. Big changes coming?
AI Summary
Vir Biotechnology, Inc. announced on January 24, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its key executives.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may affect the company's strategic direction and operational stability.
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Registrant
- January 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 1800 Owens Street, Suite 900, San Francisco, California 94158 (address) — Principal Executive Offices
- 415-906-4324 (phone_number) — Registrant's Telephone Number
FAQ
Who are the departing directors or officers?
The filing indicates the departure of certain officers and directors but does not name them specifically in the provided text.
Who are the newly elected directors?
The filing states that directors have been elected but does not provide their names in the provided text.
What specific changes were made to compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers but does not detail the specifics in the provided text.
When did these changes become effective?
The earliest event reported is dated January 24, 2025, and the date as of change is also January 24, 2025.
What is Vir Biotechnology's primary business?
Vir Biotechnology, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2025-01-30 07:51:27
Key Financial Figures
- $0.0001 — ange on which registered Common stock, $0.0001 par value VIR Nasdaq Global Select Mark
Filing Documents
- vir-20250124.htm (8-K) — 23KB
- 0001628280-25-003073.txt ( ) — 177KB
- vir-20250124.xsd (EX-101.SCH) — 2KB
- vir-20250124_def.xml (EX-101.DEF) — 15KB
- vir-20250124_lab.xml (EX-101.LAB) — 26KB
- vir-20250124_pre.xml (EX-101.PRE) — 16KB
- vir-20250124_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIR BIOTECHNOLOGY, INC. Date: January 30, 2025 By: /s/ Marianne De Backer Marianne De Backer, M.Sc., Ph.D., MBA Chief Executive Officer